ACTA ENDOCRINOLOGICA (BUC)

The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Journal Impact Factor - click here.

Year Volume Issue First page
10.4183/aeb.
Author
Title
Abstract/Title
From through

  • Case Report

    Fica SV, Popescu L, Ciprut T, Ardeleanu C, Terzea D, Trifanescu R, Coculescu M

    Beneficial effects of gonadotropin releasing hormone analogs in pulmonary lymphangioleiomyomatosis

    Acta Endo (Buc) 2005 1(1): 109-119 doi: 10.4183/aeb.2005.109

    Abstract References
    OBJECTIVE: To report an unusual cause of respiratory failure in a 33-year old Caucasian woman, diagnosed at 26 years with pulmonary lymphangioleiomyomatosis (LAM) and treated with gonadoliberin analogs (aGnRH) four years.\r\nMETHODS: The respiratory failure was diagnosed on functional tests (spirometry, oxymetry, diffusing capacity of carbon monoxide). High resolution chest computed tomographic (HRCT) scan and open lung biopsy with specific immunohistochemistry certified the diagnosis.\r\nRESULTS: The diagnosis of pulmonary LAM was established after one year on chest HRCT and lung biopsy which revealed the proliferation of smooth muscle of pulmonary vessels, positive for actin, desmin, vimentin, estrogen- and progesterone- receptors. Spirometry revealed mixed obstructive and restrictive dysfunction. A correlation between worsening of dyspnea and estradiol peaks occurred during three gestation periods. Despite a short treatment with medroxyprogesterone 10 mg/day and tamoxifen (20 mg/day), the patient?s symptoms and pulmonary function tests worsened. aGnRH treatment improved both symptoms and pulmonary function tests during the first year and was associated with a slow decline in pulmonary function tests and stabilization of the cystic lesions during the following 3 years. The patient did not develop LAM-complications such as: pneumothorax, chylothorax, or hemoptysis.\r\nCONCLUSION: Treatment with aGnRH is effective in slowing the evolution of pulmonary LAM.
    1. Johnson S. Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms. Thorax 1999;54:254-264. [CrossRef]
    2. Ferrans VJ, Yu ZX, Nelson WK et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch. 2000;67:311-329. [CrossRef]
    3. Rosai J ed. Rosai and Ackerman?s Surgical Pathology. 9th ed. Mosby. 2004.
    4. Urban T, Lazor R, Lacronique J et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d?Etudes et de Recherche sur les Maladies ?Orphelines? Pulmonaires (GERM?O?P). Medicine (Baltimore) 1999;78:321-337. [CrossRef]
    5. Denoo X, Hermans G, Degives R et al. Successful treatment of pulmonary lymphangioleiomyomatosis with progestins: a case report. Chest 1999;115:276-279. [CrossRef]
    6. Klein M, Krieger O, Ruckser R et al. Treatment of lymphangioleiomyomatosis by ovariectomy, interferon alpha 2b and tamoxifen?a case report. Arch Gynecol Obstet. 1992;252:99-102. [CrossRef]
    7. Laverdiere C, David M, Dubois J et al. Improvement of disseminated lymphangiomatosis with recombinant interferon therapy. Pediatr Pulmonol. 2000;29:321-324. [CrossRef]
    8. Boehler A, Speich R, Russi EW et al. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med. 1996;335:1275-1280. [CrossRef]
    9. Desurmont S, Bauters C, Copin MC et al. [Treatment of pulmonary lymphangioleiomyomatosis using a GnRH agonist]. Rev Mal Respir. 1996;13:300-304.
    10. Rossi GA, Balbi B, Oddera S et al. Response to treatment with an analog of the luteinizinghormone- releasing hormone in a patient with pulmonary lymphangioleiomyomatosis. Am Rev Respir Dis. 1991;143:174-176.
    11. Clementsen PS, Folke K, and Faurschou P. [Lymphangioleiomyomatosis]. Ugeskr Laeger. 1995;157:298-299.
    12. Chu SC, Horiba K, Usuki J et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999;115:1041-1052. [CrossRef]
    13. Bonetti F, Chiodera PL, Pea M et al. Transbronchial biopsy in lymphangiomyomatosis of the lung. HMB45 for diagnosis. Am J Surg Pathol. 1993;17:1092-1102. [CrossRef]
    14. Logginidou H, Ao X, Russo I et al. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Chest 2000;117:25-30. [CrossRef]
    15. Matsui K, Takeda K, Yu ZX et al. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. Am J Respir Crit Care Med. 2000;161:1002-10
    16. Baldi S, Papotti M, Valente ML et al. Pulmonary lymphangioleiomyomatosis in postmenopausal women: report of two cases and review of the literature. Eur Respir J. 1994;7:1013-1016.
    17. Hu H, Wang W, and Wang X. [Clinical analysis of pulmonary lymphangioleiomyomatosis]. Zhonghua Yi Xue Za Zhi. 2001;81:1256-1260.
    18. Kaptanoglu M, Hatipoglu A, Kutluay L et al. Bilateral chylothorax caused by pleuropulmonary lymphangiomyomatosis: a challenging problem in thoracic surgery. Scand Cardiovasc J. 2001;35:151- 154. [CrossRef]
    19. Usuki J, Horiba K, Chu SC et al. Immunohistochemical analysis of proteins of the Bcl-2 family in pulmonary lymphangioleiomyomatosis: association of Bcl-2 expression with hormone receptor status. Arch Pathol Lab Med. 1998;122:895-902.
    20. Moss J, DeCastro R, Patronas NJ et al. Meningiomas in lymphangioleiomyomatosis. JAMA 2001;286:1879-1881.
    21. Carsillo T, Astrinidis A, and Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000;97:6085-6090. [CrossRef]
    22. Sato T, Seyama K, Fujii H et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet. 2002;47:20-28. [CrossRef]
    23. Yu J, Astrinidis A, and Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med. 2001;164:1537-1540.
    24. Inoue Y, King TE, Jr., Barker E et al. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2002;166:765-773. [CrossRef]
    25. Valencia JC, Matsui K, Bondy C et al. Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis. J Investig Med. 2001;49:421-433. [CrossRef]
    26. Evans SE, Colby TV, Ryu JH et al. Transforming growth factor-beta 1 and extracellular matrixassociated fibronectin expression in pulmonary lymphangioleiomyomatosis. Chest 2004;125:1063- 1070. [CrossRef]
    27. Matsui K, Takeda K, Yu ZX et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2000;124:267-275.
    28. Hayashi T, Fleming MV, Stetler-Stevenson WG et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol. 1997;28:1071-1078. [CrossRef]
    29. Dweik RA, Laskowski D, Ozkan M et al. High levels of exhaled nitric oxide (NO) and NO synthase III expression in lesional smooth muscle in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol. 2001;24:414-418.
    30. Johnson SR and Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med. 1999;160:628-633.
    31. Zanella A, Toppan P, Nitti D et al. Pulmonary lymphangioleiomyomatosis: a case report in postmenopausal woman treated with pleurodesis and progesterone (medroxyprogesterone acetate). Tumori 1996;82:96-98.
    32. Kitaichi M and Izumi T. Lymphangioleiomyomatosis. Curr Opin Pulm Med. 1995;1:417-424.
    33. Svendsen TL, Viskum K, Hansborg N et al. Pulmonary lymphangioleiomyomatosis: a case of progesterone receptor positive lymphangioleiomyomatosis treated with medroxyprogesterone, oophorectomy and tamoxifen. Br J Dis Chest 1984;78:264-271. [CrossRef]
    34. Zahner J, Borchard F, Fischer H et al. [Successful therapy of a postpartum lymphangioleiomyomatosis. Case report and literature review]. Schweiz Med Wochenschr. 1994;124:1626-1632.
    35. Pechet TT, Meyers BF, Guthrie TJ et al. Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant 2004;23:301-308. [CrossRef]
  • Endocrine Care

    Nanu M, Ardeleanu IS, Brezan F, Nanu I, Apostol A, Moldovanu F, Lazarescu H, Gheorghiu ML, Kozma A

    Neonatal Screening for Congenital Hypothyroidism in Romania: Data From Medilog Medical Information Registry

    Acta Endo (Buc) 2019 15(2): 209-214 doi: 10.4183/aeb.2019.209

    Abstract
    Objective. Congenital hypothyroidism (CH) is one of the common preventable causes of intellectual disability in neonates, by early detection through neonatal screening. We present the 8-year experience of the National Institute for Mother and Child Health (INSMC) in using MEDILOG national registry for the neonatal screening of CH. Methods. Neonatal screening for CH, done by TSH measurement in dried blood spot, is organized in 5 regional centers, each with a reference laboratory. Results. In 2018 80% of all the newborns, from 80% of the maternity hospitals, were registered in MEDILOG. After re-testing of TSH and T4/FT4 from venous blood in positive cases, the incidence of confirmed CH in 2018 was 1/3576 - 1/ 4746. In INSMC center (which includes 26 counties and Bucharest, out of 41 counties), in 2018 the incidence of positive CH cases at screening was 1/2094 (TSH cut-off ≥17 mIU/L) and of confirmed CH cases 1/3576 newborns. For positive screening cases, the median duration from birth to the INSMC laboratory result was 19 days: median of 9 days between screening and laboratory registration and 6 days between registration and test result. Conclusion. MEDILOG registry is a practical instrument for monitoring the steps of neonatal CH screening, the incidence of CH, the evolution of the diagnosed cases, for evaluation of iodine deficiency (by neonatal TSH), and also for research, with the aim of improving early disease detection and treatment.
  • Endocrine Care

    Ardeleanu I, Caragheorgheopol A

    The Value of Cortisol Measurement in Prolonged Fever because of Low Respiratory Tract Infection in Children

    Acta Endo (Buc) 2013 9(3): 397-404 doi: 10.4183/aeb.2013.397

    Abstract
    Context. The role of cortisol in modulating the inflammatory response upon an immune challenge is well documented. Objectives. We aim to assess cortisol levels related to inflammatory status in children with persistent fever and low respiratory tract infection (LRTI). Patients and methods. Thirty five children hospitalised with fever above 38oC for more than 10 days and clinical features of LRTI were enrolled. Immunoglobulins, C-reactive protein (CRP) and cortisol were measured at the admission and after 12 days. Results. From 35 patients, 29 had a satisfactory evolution and 7 had a complicated course of disease. In patients with a satisfactory outcome, the mean value of cortisol at the admission was at the upper limit of the reference range, CRP and immunoglobulin G (IgG) are significantly higher versus reference limit (p<0.05). Children with a severe evolution had a significantly lower cortisol level than those with good evolution, at the lower limit of reference range (p<0.001), and correlated with low levels of CRP and immunoglobulins; cortisol and CRP showed a slight increase after 12 days corresponding with a prolonged course of disease.Conclusions. Cortisol measurement might aid value in early identification of patients requiring initiation of antibiotherapy, corticotherapy or other intensive management strategies.